Skip header and navigation

Refine By

164 records – page 1 of 17.

55 cases of allergic reactions to hair dye: a descriptive, consumer complaint-based study.

https://arctichealth.org/en/permalink/ahliterature71451
Source
Contact Dermatitis. 2002 Nov;47(5):299-303
Publication Type
Article
Date
Nov-2002
Author
H. Søsted
T. Agner
K E Andersen
T. Menné
Author Affiliation
The National Allergy Research Centre for Consumer Products, Department of Dermatology, University of Copenhagen, Gentofte Hospital, Denmark.
Source
Contact Dermatitis. 2002 Nov;47(5):299-303
Date
Nov-2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Adverse Drug Reaction Reporting Systems
Aged
Allergens - adverse effects
Denmark - epidemiology
Dermatitis, Allergic Contact - epidemiology - etiology - pathology
Facial Dermatoses - chemically induced - epidemiology - pathology
Female
Hair Preparations - adverse effects
Humans
Male
Middle Aged
Phenylenediamines - adverse effects
Scalp Dermatoses - chemically induced - epidemiology - pathology
Abstract
Severe facial and scalp dermatitis following the use of permanent hair dyes has been reported in several cases. Para-phenylenediamine (PPD) is known as a potent contact allergen, and PPD is allowed in hair dye at a concentration of 6%. Hair dye reactions are usually diagnosed by the patients themselves, and adverse reactions to hair dye may not necessarily be recorded by the health care system, unless the reactions are especially severe. Based on this assumption, we suspected that hair dye dermatitis was occurring more frequently than reported in the literature. Consumer complaint-based data were obtained by advertising for persons with adverse reactions to hair dye. Among those responding to the advertisement, 55 cases of severe, acute allergic contact dermatitis were identified. The main symptoms were severe oedema of the face, scalp and ears, and clinically this was often mistaken for angio-oedema. The 55 cases comprised a total of 75 visits to the health service and 5 admissions to hospital. 18 persons had sick leave, which supports the impression of very severe dermatitis reactions. 60% were treated with antihistamine, while 52% were treated with corticosteroids. 29% of the cases were patch tested and all were found positive to PPD. Our data presented here clearly show that PPD and its derivatives in hair dye at the present concentrations presents a significant health risk for the population. Furthermore, the severe acute allergic skin reactions are often misdiagnosed in the health care system. The frequency of allergic contact dermatitis resulting from hair dye is likely to be underestimated. New methods to survey the frequency of adverse reactions should be considered.
PubMed ID
12534535 View in PubMed
Less detail

Adherence to national guidelines for initiation of antiretroviral regimens in HIV patients: a Danish nationwide study.

https://arctichealth.org/en/permalink/ahliterature137186
Source
Br J Clin Pharmacol. 2011 Jul;72(1):116-24
Publication Type
Article
Date
Jul-2011
Author
Tonny S Petersen
Stig E Andersen
January Gerstoft
Kristina Thorsteinsson
Carsten S Larsen
Gitte Pedersen
Court Pedersen
Niels Obel
Author Affiliation
Department of Clinical Pharmacology, Copenhagen University Hospital, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark. tsp@person.dk
Source
Br J Clin Pharmacol. 2011 Jul;72(1):116-24
Date
Jul-2011
Language
English
Publication Type
Article
Keywords
Adult
Anti-HIV Agents - administration & dosage
Antiretroviral Therapy, Highly Active - methods - standards
Cohort Studies
Denmark
Drug Administration Schedule
Female
Guideline Adherence
HIV Infections - drug therapy
Humans
Male
Patient compliance
Practice Guidelines as Topic
Regression Analysis
State Medicine
Treatment Outcome
Abstract
To determine the adherence to the national guidelines for start of highly active antiretroviral treatment (HAART) in HIV infected patients.
We used a Danish nationwide cohort of HIV infected patients to calculate the fraction of patients who in the period 1997-2006 started HAART according to the guidelines from The Danish Society of Infectious Diseases. We used Kaplan-Meier tables to estimate time from fulfilling the criteria for start of HAART to initiation of the treatment. Cox regression and logistic regression was used to identify risk factors for delayed initiation of treatment and chance of being included in clinical trials.
The study included 3223 patients, 74% of whom initiated HAART in the study period. Ninety-four% fulfilled the criteria for start of HAART, with minor differences over calendar periods. Ninety-four% initiated a recommended regimen or were included in a clinical trial. Intravenous drug use predicted initiation of a non-recommended regimen and delay in start of HAART, while non-Caucasians were less likely to be included in clinical trials.
In a Western world setting, the adherence to national guidelines for start of HAART can be high. We suggest that simplicity of the guidelines, centralization of treatment and involvement of local clinicians in the development of guidelines are of major importance for high adherence to treatment guidelines.
Notes
Cites: Stud Health Technol Inform. 2008;136:339-4418487754
Cites: Scand J Infect Dis. 2010 Dec;42(11-12):917-2320840000
Cites: Nature. 2009 Sep 17;461(7262):336-919759594
Cites: Antivir Ther. 2009;14(7):995-100019918103
Cites: Health Serv Res. 2000 Mar;34(7):1429-4810737446
Cites: Br J Clin Pharmacol. 2001 Mar;51(3):213-711298066
Cites: J Gen Intern Med. 2001 Sep;16(9):625-3311556944
Cites: Clin Infect Dis. 2003 Mar 15;36(6):803-1112627367
Cites: Med Care. 1994 Mar;32(3):202-138145598
Cites: N Engl J Med. 1994 Nov 17;331(20):1350-37935706
Cites: BMJ. 1998 Sep 26;317(7162):858-619748183
Cites: JAMA. 1999 Jun 23-30;281(24):2305-1510386555
Cites: HIV Med. 2004 Nov;5(6):415-2015544693
Cites: AIDS. 2005 May 20;19(8):815-2215867496
Cites: Scand J Infect Dis. 2005;37(5):338-4316051569
Cites: Cochrane Database Syst Rev. 2006;(2):CD00025916625533
Cites: J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):20-917091020
Cites: Ann Intern Med. 2007 Jan 16;146(2):87-9517227932
Cites: Br J Clin Pharmacol. 2007 Dec;64(6):722-517953721
Cites: HIV Med. 2008 Jan;9(1):47-5618199172
Cites: Ugeskr Laeger. 2008 Feb 25;170(9):740-418307962
Cites: J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):377-8318176324
Cites: JAMA. 2008 Aug 6;300(5):555-7018677028
PubMed ID
21306418 View in PubMed
Less detail

Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.

https://arctichealth.org/en/permalink/ahliterature105792
Source
Clin Toxicol (Phila). 2014 Jan;52(1):39-43
Publication Type
Article
Date
Jan-2014
Author
A B Petersen
S E Andersen
M. Christensen
H L Larsen
Author Affiliation
Department of Clinical Pharmacology, Bispebjerg Hospital , Copenhagen , Denmark.
Source
Clin Toxicol (Phila). 2014 Jan;52(1):39-43
Date
Jan-2014
Language
English
Publication Type
Article
Keywords
Adult
Antipsychotic Agents - administration & dosage - adverse effects - therapeutic use
Basal Ganglia Diseases - chemically induced - epidemiology
Benzodiazepines - administration & dosage - adverse effects - therapeutic use
Central Nervous System - drug effects
Denmark - epidemiology
Depression, Chemical
Drug Overdose - epidemiology - mortality
Electrocardiography - drug effects
Female
Hospitals, Psychiatric
Humans
Inpatients
Long QT Syndrome - chemically induced
Male
Neuroleptic Malignant Syndrome - physiopathology
Psychotic Disorders - complications - drug therapy
Retrospective Studies
Risk assessment
Abstract
In 2012, Danish psychiatrist raised concerns regarding the use of high-dose olanzapine in the treatment of patients. The present study was part of an audit carried out by the Mental Health Services of the Capitol Region of Denmark regarding this topic. Objective. To assess the potential risks associated with high-dose olanzapine treatment (> 40 mg daily) in inpatient psychiatric units.
The study was an observational case series based on review of patient charts. The main inclusion criterion was treatment with at least one daily dose > 40 mg olanzapine during the index admission in the period between 1st of January and 15th of March 2012. Six additional criteria were applied in order to target the subgroup of patients most likely to have experienced an adverse event due to treatment with olanzapine. The physician order entry system and the central patient register containing patient specific information about diagnoses and treatments were used for identification of study population.
The 91 patients included in the study received maximum daily doses of olanzapine ranging from 45 to 160 mg and in 25% of patients, the total antipsychotic load exceeded 2000 mg of chlorpromazine equivalents. Extrapyramidal symptoms and sedation were the most frequent adverse events with frequencies of 27% and 25%, respectively. Furthermore, other well-known adverse events such as weight gain (14%), hypotension (2%), neuroleptic malignant syndrome (2%) and corrected QT-interval (QTc) prolongation (1%) were also observed in some patients. Five patients died and in two of these cases, olanzapine was concluded to be a possible contributing cause of death.
Increased frequency of extrapyramidal symptoms and sedation as well as severe toxicity was observed in patients treated with up to 160 mg olanzapine per day. In order to prevent harmful outcomes, the clinicians should be ready to act appropriately if toxic effects of olanzapine occur. Treatment cessation should be immediate if serious adverse events such as neuroleptic malignant syndrome arise.
PubMed ID
24313745 View in PubMed
Less detail

[Adverse effects of drugs in patients with heart disease lead to hospital care]

https://arctichealth.org/en/permalink/ahliterature53815
Source
Lakartidningen. 2001 Nov 21;98(47):5349-53
Publication Type
Article
Date
Nov-21-2001
Author
C. Sarlöv
E. Andersén-Karlsson
C. von Bahr
Author Affiliation
Klinisk farmakologi, VO Medicin, Södersjukhuset, Stockholm.
Source
Lakartidningen. 2001 Nov 21;98(47):5349-53
Date
Nov-21-2001
Language
Swedish
Publication Type
Article
Keywords
Adverse Drug Reaction Reporting Systems
Cardiovascular Diseases - drug therapy
Drug Interactions
English Abstract
Female
Heart Diseases - drug therapy
Humans
Male
Patient Admission - statistics & numerical data
Pharmaceutical Preparations - adverse effects
Polypharmacy
Retrospective Studies
Sweden
Abstract
Polypharmacy in patients with cardiovascular disease leads to an increased risk of developing adverse effects. At the Department of Internal Medicine at Stockholm Söder Hospital we studied computerized records and discovered that 14% of those hospitalized patients who were on drug treatment for cardiovascular diseases were admitted due to problems or symptoms possibly caused by their drugs. Interactions were less common; the symptoms which warranted hospitalization were more often caused by additive pharmacological effects. Obviously, adverse effects of drugs decrease quality of life, cause unnecessary suffering and treatment, and are expensive for the health care system. Screening of computerized records helps us detect adverse effects, and facilitates prevention.
PubMed ID
11763634 View in PubMed
Less detail

[Aimed health check-ups can be justified].

https://arctichealth.org/en/permalink/ahliterature205178
Source
Tidsskr Nor Laegeforen. 1998 May 30;118(14):2208
Publication Type
Article
Date
May-30-1998
Author
H L Leira
K E Andersen
Author Affiliation
Arbeidsmedisinsk avdeling Regionsykehuset i Trondheim.
Source
Tidsskr Nor Laegeforen. 1998 May 30;118(14):2208
Date
May-30-1998
Language
Norwegian
Publication Type
Article
Keywords
Humans
Norway
Physical Examination
Preventive Health Services
PubMed ID
9656820 View in PubMed
Less detail

Allergic contact dermatitis from octylisothiazolinone.

https://arctichealth.org/en/permalink/ahliterature112943
Source
Contact Dermatitis. 2013 Jul;69(1):49-52
Publication Type
Article
Date
Jul-2013
Author
Anja P Mose
Simon Frost
Ulf Ohlund
Klaus E Andersen
Author Affiliation
Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense C, Denmark.
Source
Contact Dermatitis. 2013 Jul;69(1):49-52
Date
Jul-2013
Language
English
Publication Type
Article
Keywords
Adult
Causality
Denmark - epidemiology
Dermatitis, Allergic Contact - diagnosis - epidemiology - etiology
Dermatitis, Occupational - diagnosis - epidemiology - etiology
Female
Humans
Male
Middle Aged
Occupational Exposure - adverse effects - statistics & numerical data
Paint - adverse effects
Patch Tests - statistics & numerical data
Risk factors
Thiazoles - administration & dosage - adverse effects
Workplace
Young Adult
Abstract
Octylisothiazolinone is a biocide that has been reported as a moderate, but rare contact allergen.
To investigate the occurrence of octylisothiazolinone contact allergy and allergic contact dermatitis diagnosed and registered in the Allergen Bank at Odense University Hospital during the past 20 years. Octylisothiazolinone has been used for targeted testing only.
All octylisothiazolinone-patch test results registered in the Allergen Bank between January 1992 and February 2012 were analyzed.
A total of 20 out of 648 patients patch tested with octylisothiazolinone had positive reactions. The majority of the patients (90%) with relevant sensitizations to octylisothiazolinone had been exposed in occupational settings and most patients were painters.
Octylisothiazolinone is a relevant sensitizer.
PubMed ID
23782358 View in PubMed
Less detail

An 8-year experience with routine SL mix patch testing supplemented with Compositae mix in Denmark.

https://arctichealth.org/en/permalink/ahliterature194248
Source
Contact Dermatitis. 2001 Jul;45(1):29-35
Publication Type
Article
Date
Jul-2001
Author
E. Paulsen
K E Andersen
B M Hausen
Author Affiliation
Department of Dermatology, Odense University Hospital, DK-5000 Odense C, Denmark.
Source
Contact Dermatitis. 2001 Jul;45(1):29-35
Date
Jul-2001
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Allergens - adverse effects - diagnostic use
Asteraceae - adverse effects
Denmark - epidemiology
Dermatitis, Allergic Contact - diagnosis - epidemiology - etiology
Dermatitis, Occupational - diagnosis - epidemiology - etiology
Female
Humans
Male
Middle Aged
Patch Tests - standards
Plant Extracts - adverse effects - diagnostic use
Prevalence
Sesquiterpenes - adverse effects - diagnostic use
Abstract
Routine patch testing with sesquiterpene lactone (SL) mix, supplemented with Compositae mix (CM) and other Compositae extracts and allergens where appropriate, was evaluated over an 8-year period. 190 of 4386 patients tested (4.3%) were Compositae-sensitive, 143 females (mean age 51.5 years) and 47 males (mean age 55 years), and 83% of reactions considered clinically relevant. 22% were suspected of occupational sensitization/dermatitis. 62% had a contact allergy to 2 or more compounds, most often to nickel, fragrance and colophonium. SL mix detected 65%, CM 87% of Compositae-allergic patients, and the overall detection rate with both mixes was 93%. Few irritant reactions and no cases of clear-cut active sensitization were recorded with the mixes, but our results emphasize the importance of differentiating late-appearing reactivation reactions from patch test sensitization. The weakly positive CM reactions could reflect some irritancy, but as they were associated with fragrance and/or colophonium allergy to a higher degree than weakly positive SL mix reactions, they probably represented cross-reactions. In conclusion, the detection rate with SL mix was high enough to support its continued use as a screening mix and it was very well and rather safely supplemented by aimed testing with CM.
PubMed ID
11422265 View in PubMed
Less detail

An epidemiological study of disability in 4-year-old children from a birth cohort in Frederiksborg County, Denmark.

https://arctichealth.org/en/permalink/ahliterature37730
Source
Dan Med Bull. 1990 Apr;37(2):182-5
Publication Type
Article
Date
Apr-1990
Author
E. Andersen
H C Fledelius
M. Føns
R. Haugsted
Author Affiliation
Department of Pediatrics, Frederiksborg County Hospital, Hillerød.
Source
Dan Med Bull. 1990 Apr;37(2):182-5
Date
Apr-1990
Language
English
Publication Type
Article
Keywords
Abnormalities - epidemiology
Cerebral Palsy - epidemiology
Child, Preschool
Cohort Studies
Denmark
Epilepsy - epidemiology
Female
Hearing Disorders - epidemiology
Humans
Male
Mental Retardation - epidemiology
Research Support, Non-U.S. Gov't
Speech Disorders - epidemiology
Vision Disorders - epidemiology
Abstract
In an epidemiological study of a county cohort of 4,138 liveborn children, surveyed at age four, 45 had disability (1.1%). The following period prevalences from birth to age four in per mille were found: motor handicap 5.1, to include cerebral palsy 4.1, myelomeningocele and hydrocephalus 0.5, and metabolic disorders 0.5; severe mental retardation 2.9, mild 1.4, subnormality 2.7; epilepsy 4.6; severe visual defect 1.4; severe auditory defect 0.7. Perinatal damage alone was likely in only three children out of 45. Two thirds had a prenatal cause or a combination of prenatal and perinatal causes. Birth asphyxia seemed to be a rare cause of motor disability and mental retardation. Prematurity per se gave a risk of spastic diplegia, but not of mental retardation. Among the mentally retarded, half were light for gestational age, and in more than half, the damage occurred prenatally.
PubMed ID
2344771 View in PubMed
Less detail

An on-site test battery to evaluate giant slalom skiing performance.

https://arctichealth.org/en/permalink/ahliterature228427
Source
J Sports Med Phys Fitness. 1990 Sep;30(3):276-82
Publication Type
Article
Date
Sep-1990
Author
R E Andersen
D L Montgomery
R A Turcotte
Author Affiliation
Human Performance Lab, McGill University, Montreal, Quebec, Canada.
Source
J Sports Med Phys Fitness. 1990 Sep;30(3):276-82
Date
Sep-1990
Language
English
Publication Type
Article
Keywords
Adolescent
Analysis of Variance
Canada
Exercise - physiology
Exercise Test
Humans
Lactates - blood
Male
Physical Fitness
Skiing
Abstract
The purpose of this study was to determine if an on-site test battery would distinguish among three levels of giant slalom skiing ability. The test battery consisted of a 20-m shuttle run test, Wingate 60s cycling test, hexagonal obstacle test, high box test, double leg jumping test and vertical jump test. These tests were selected since previous studies have identified aerobic endurance, anaerobic endurance, power and agility as important components for Alpine skiers. Both construct validity and criterion related validity of the test battery were examined using data from 11 club skiers, 14 divisional level skiers, and 9 provincial level skiers. To establish construct validity, univariate F tests examined differences among the three levels of skiers. Significant (P less than 0.05) differences were found between the club skiers and the better skiers (divisional and provincial level) for the following test variables: peak power, mean power, and post-exercise lactate for a 60s Wingate cycle ergometer test, high box test, hexagonal obstacle test, double leg jumping test, and shuttle run test. Criterion related validity was established since there were significant correlations between giant slalom performance time and the hexagonal obstacle test (r = 0.82), high box test (r = -0.80), and double leg jumping (r = -0.86). These data illustrate that an on-site test battery can be used to distinguish among giant slalom Alpine skiers.
PubMed ID
2266759 View in PubMed
Less detail

Antenatal and perinatal conditions correlated to handicap among 4-year-old children.

https://arctichealth.org/en/permalink/ahliterature38167
Source
Am J Perinatol. 1989 Apr;6(2):258-67
Publication Type
Article
Date
Apr-1989
Author
K. Holst
E. Andersen
J. Philip
I. Henningsen
Author Affiliation
Department of Obstetrics and Gynecology, Y Rigshospitalet, University of Copenhagen, Denmark.
Source
Am J Perinatol. 1989 Apr;6(2):258-67
Date
Apr-1989
Language
English
Publication Type
Article
Keywords
Cerebral Palsy - etiology
Child, Preschool
Cohort Studies
Denmark
Epilepsy - etiology
Female
Hearing Disorders - etiology
Humans
Infant, Newborn
Infant, Newborn, Diseases - complications
Mental Retardation - etiology
Obstetric Labor Complications
Parity
Pregnancy
Pregnancy Complications
Research Support, Non-U.S. Gov't
Risk factors
Vision Disorders - etiology
Abstract
The purpose of this study was to investigate the impact of maternal prepregnancy and pregnancy-related risk factors, complicated delivery, and perinatal morbidity on subsequent handicaps in children. We surveyed a birth cohort of 4102 mothers and 4138 children in Frederiksborg County, Denmark. Maternal risk factors were defined according to guidelines published by the Danish National Board of Health, and perinatal morbidity and handicaps according to World Health Organization guidelines. The incidence of handicaps: (cerebral palsy, mental retardation [mild and severe], epilepsy, severe defects of vision and hearing); was 44 of 4038 children (twins and neonatal deaths were excluded). A combination of three or more maternal risk factors was found to be a predictor of risk for children with later handicaps; the incidence of handicaps was 11 times higher than in mothers with no risk factors. Eleven percent of all mothers had three or more risk factors and they had 43% of the handicapped children. Multiparity increased the risk in all risk categories. Of complications at delivery, intrapartum asphyxia, as evident from Apgar scores of less than 7 at 1 minute and less than 10 at 10 minutes in particular, was a strong predictor of a later handicap. Premature rupture of membranes for more than 24 hours was also significantly associated with later handicaps. Perinatal morbidity was correlated with a later handicap. The perinatal complication most strongly associated with later handicaps was low birthweight. Forty-eight percent of the affected children had a birthweight of less than 2500 gm and were small for gestational age. We conclude that the incidence of handicaps could possibly be reduced if the causes of the following maternal risk factors were identified and, if possible, eliminated: previous delivery of a child with a birthweight less than 2500 gm, previous delivery of a stillborn child, repeated abortions, severe infection during pregnancy, intrauterine growth retardation, and preterm delivery. Improved intrapartum diagnosis and prevention of asphyxia and treatment of children born with low Apgar scores would reduce the incidence of handicaps, as would intervention to prevent premature rupture of the membranes of more than 24 hour's duration.
PubMed ID
2712925 View in PubMed
Less detail

164 records – page 1 of 17.